Past events
Final Analysis of Phase 2b/3 Clinical Trial for CVnCoV – Webcast & Conference Call
July 1, 2021
On Wednesday, June 30, 2021, CureVac N.V. (Nasdaq: CVAC) announced results from the final analysis of its 40,000 subject international pivotal Phase 2b/3 study (the HERALD study) of the first-generation COVID-19 vaccine candidate, CVnCoV.
The company hosted a conference call and webcast on Thursday, July 1, 2021, 2:00 p.m. CET / 8:00 a.m. EDT.
A replay of the webcast can be found under "Links".
Downloads
Links
Final Analysis of Phase 2b/3 Clinical Trial of CVnCoV – Press Conference in German Language
July 01, 2021
On Wednesday, June 30, 2021, CureVac N.V. (Nasdaq: CVAC) announced results from the final analysis of its 40,000 subject international pivotal Phase 2b/3 study (the HERALD study) of the first-generation COVID-19 vaccine candidate, CVnCoV.
The company hosted a press conference in German language on Thursday, July 1, 2021, 10:00 a.m. CEST.
The corresponding presentation slides can be found under "Downloads". An replay of the press conference can be found under "Links".
Downloads
- Press Release
- Presentation (German only)
Links
- Replay Webcast (German only)
Annual General Meeting 2021
June 24, 2021
The Annual General Meeting (the “AGM”) of Shareholders of CureVac N.V. was held on Thursday, June 24, 2021, at 2:00 p.m. Central European Summer Time. The AGM was held entirely virtually, without physical attendance of shareholders or others with meeting rights. You were not be able to vote during the AGM and your proxy to vote had to be received no later than 5:59 a.m. Central European Summer Time on Tuesday, June 22, 2021.
Update on Phase 2b/3 Clinical Trial for CureVac’s First-Generation COVID-19 Vaccine candidate, CVnCoV – Webcast & Conference Call
June 17, 2021
To provide an update on Phase 2b/3 clinical trial for CureVac’s first-generation COVID-19 vaccine candidate, CVnCoV, CureVac N.V. (Nasdaq: CVAC) hosted a webcast and conference call on Thursday, June 17, 2021, at 2:00 p.m. CEST / 8:00 a.m. EST.
The corresponding press release, presentation slides and transcript can be found under “Downloads”. An archived webcast can be found under "Links".
Downloads
Links
German Hauptstadtkongress Medizin und Gesundheit 2021
June 16, 2021
Virtual Panel Discussion (German only):
Medizinischer Fortschritt „Made in Germany“: Gewollt, ermöglicht und erreichbar?
Fourth Quarter and Full-Year 2020 Financial Results and Business Updates – Conference Call & Webcast
April 15, 2021
CureVac N.V. (Nasdaq: CVAC) reported financial results and business updates for the fourth quarter and full-year of 2020 on Thursday, April 15, 2021, at 4:00 p.m. CET / 10:00 a.m. EST.
Please find the corresponding press release, presentation slides, transcript as well as the archived webcast below.
Downloads
Links
Credit Suisse 2021 London Global Healthcare Conference
March 2, 2021
Virtual Event
Fireside Chat: 12:00 p.m. GMT / 7:00 a.m. EST
Leerink 10th Annual Global Healthcare Conference
February 24, 2021
Virtual Event
Presentation: 8:00 a.m. EST
Downloads
Management attending JP Morgan 39th Annual Healthcare Conference
January 11 - 14, 2021
For meeting inquiries please contact investors@curevac.com.
Third Quarter and First 9 Months 2020 Financial Results and Business Updates – Conference Call & Webcast
November 30, 2020
CureVac N.V. (Nasdaq: CVAC) announced financial results and business updates for the third quarter and first nine months of 2020 on Monday, November 30, 2020. The company hosted a conference call and webcast on the same day at 4:00 p.m. CET / 10:00 a.m. EST.
Please find the corresponding press release, presentation slides, transcript and archived webcast below.
Positive Interim Phase 1 Data of CureVac’s COVID-19 Vaccine Candidate, CVnCoV – Conference Call & Webcast
November 10, 2020
The press release, presentation and transcript can be downloaded below, the archived webcast is available through the following link.
Downloads
Links